Neurocrine biosciences reports first quarter 2025 financial results and reaffirms 2025 financial guidance

Ingrezza® (valbenazine) first-quarter 2025 net product sales of $545 million and reaffirms 2025 net product sales guidance of $2.5 - $2.6 billion crenessitytm (crinecerfont) first-quarter 2025 net product sales of $14.5 million with 413 total patient enrollment start forms initiated phase 3 registrational programs for osavampator in major depressive disorder and nbi-'568 in schizophrenia to position for next phase of growth san diego , may 5, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced its financial results for the first quarter ended march 31, 2025, and reaffirms its 2025 financial guidance. "we delivered a record number of new patient starts for ingrezza, which is especially impressive given the typically challenging first quarter.
NBIX Ratings Summary
NBIX Quant Ranking